World Vaccine Congress 2021 Day 1-2

From science to solidarity: the successes and limits of the global COVID-19 vaccine response

官方文件，没什么luan意思

Novavax COVID-19 program update

针对南非突变株，狒狒中证明，接种了2373后只有继续接种Boost dose也能产生大量的针对突变的抗体，会评估2373或其他公司针对初代疫苗priming在内的2针方案

Janssen’s single dose COVID vaccine efforts and update program

Sanofi Pasteur Recombinant COVID vaccine program

法国人的效率，什么都慢一步

老毛子's efforts towards a COVID vaccine: EpiVacCorona

Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV2 induced Disease and Blocks Viral Replication In Preclinical Studies Of SARS-CoV-2 Infection

Vaxart oral covid-19 vaccine; hold the ice and the needles

昨天更新New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses

  • Vaxart’s vaccine candidate showed higher CD8+ T-cell responses than the Pfizer and Moderna vaccines

  • Higher T-cell responses correlated to protection against COVID disease in a prospective Phase I study of first responders

  • The Vaxart vaccine candidate elicited a T cell response against SARS-Cov-2, as well as showed cross-reactivity against diverse endemic coronaviruses such as 229E, NL63, HKU1, and OC43

  • N protein responses to SARS-CoV-1 have been shown to last 17 years after infection and cross-react to SARS-CoV-2

  • Vaxart’s vaccine candidate triggered specific IgA antibodies in the mucosa. These mucosal IgA responses appeared to be cross-reactive against other coronaviruses such as SARS-CoV-1, MERS, and the endemic common cold viruses 229E, NL63, HKU1, and OC43

下载：https://investors.vaxart.com/static-files/2838785c-4358-4894-bfce-07ab68179679

mRNA COG

Rapid mRNA manufacturing for Vaccine Development

赞 (0)

相关推荐